{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:35:56Z","timestamp":1784090156619,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.seizure.2020.09.008","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T22:19:34Z","timestamp":1600208374000},"page":"27-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Risk-benefit assessment of treatment of epileptic women of childbearing age with valproic acid"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4693-7048","authenticated-orcid":false,"given":"Alejandro","family":"Qu\u00edlez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2329-9810","authenticated-orcid":false,"given":"Mariona","family":"Barald\u00e9s-Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1379-1991","authenticated-orcid":false,"given":"Yhovany","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Sanahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3651-8760","authenticated-orcid":false,"given":"Gerard","family":"Mauri-Capdevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-5968","authenticated-orcid":false,"given":"Francisco","family":"Purroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2020.09.008_bib0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1528-1167.2009.02042.x","article-title":"Drug treatment of epilepsy in the century of the ILAE : the second 50 years, 1959\u20132009","volume":"50","author":"Shorvon","year":"2009","journal-title":"Epilepsia"},{"issue":"9566","key":"10.1016\/j.seizure.2020.09.008_bib0010","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of eff ectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifi able epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.seizure.2020.09.008_bib0015","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"16","key":"10.1016\/j.seizure.2020.09.008_bib0020","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs","volume":"360","author":"Meador","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.seizure.2020.09.008_bib0025","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol."},{"issue":"16","key":"10.1016\/j.seizure.2020.09.008_bib0030","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.seizure.2020.09.008_bib0035","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/jnnp-2012-304270","article-title":"The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs","volume":"84","author":"Bromley","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.seizure.2020.09.008_bib0040","volume":"Vol 44","year":"2018"},{"key":"10.1016\/j.seizure.2020.09.008_bib0045","unstructured":"Sanidad M. \u00c1cido Valproico: Nuevas Medidas Para Evitar La Exposici\u00f3n Durante El Embarazo. https:\/\/www.aemps.gob.es\/informa\/notasinformativas\/medicamentosusohumano-3\/seguridad-1\/2018\/ni-muh_fv_3-acido-valproico\/?lang=ca."},{"issue":"1","key":"10.1016\/j.seizure.2020.09.008_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12884-018-1842-x","article-title":"Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach?","volume":"18","author":"Macfarlane","year":"2018","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.seizure.2020.09.008_bib0055","series-title":"EURAP: An International Registry of Antiepileptic Drugs and Pregnancy","author":"Tomson","year":"2018"},{"issue":"11","key":"10.1016\/j.seizure.2020.09.008_bib0060","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(05)70224-6","article-title":"Birth defects after prenatal exposure to antiepileptic drugs","volume":"4","author":"Perucca","year":"2005","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.seizure.2020.09.008_bib0065","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","article-title":"Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry","volume":"10","author":"Tomson","year":"2011","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.seizure.2020.09.008_bib0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.6606","article-title":"Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit\/hyperactivity disorder in offspring","volume":"2","author":"Christensen","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.seizure.2020.09.008_bib0075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.seizure.2009.11.008","article-title":"Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study","volume":"19","author":"Mawer","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2020.09.008_bib0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.seizure.2015.02.020","article-title":"The impact of seizures on pregnancy and delivery","volume":"28","author":"Sveberg","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2020.09.008_bib0085","series-title":"Valproate MHRA Guidance: Limitations and Opportunities","first-page":"1","author":"Watkins","year":"2019"},{"key":"10.1016\/j.seizure.2020.09.008_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2019.06.031","article-title":"Why do some women with epilepsy use valproic acid despite current guidelines? A single-center cohort study","volume":"98","author":"Bosak","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.seizure.2020.09.008_bib0095","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.seizure.2020.03.015","article-title":"The impact and challenges of the 2018 MHRA statement on the use of sodium valproate in women of childbearing age during the first year of implementation, in a UK epilepsy centre","volume":"79","author":"Davies","year":"2020","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2020.09.008_bib0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ane.13005","article-title":"Valproate-associated foetal malformations- rates of occurrence, risks in attempted avoidance","volume":"139","author":"Vajda","year":"2019","journal-title":"Acta Neurol. Scand."},{"issue":"1","key":"10.1016\/j.seizure.2020.09.008_bib0105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/epi.16407","article-title":"Doing without valproate in women of childbearing potential with idiopathic generalized epilepsy: implications on seizure outcome","volume":"61","author":"Cerulli Irelli","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.09.008_bib0110","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fneur.2020.00330","article-title":"Shifting valproic acid to Levetiracetam in women of childbearing age with epilepsy: a retrospective investigation and review of the literature","volume":"11","author":"Kuo","year":"2020","journal-title":"Front Neurol."},{"key":"10.1016\/j.seizure.2020.09.008_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106947","article-title":"Evaluation of adverse drug reaction profile of antiepileptic drugs in persons with epilepsy: a cross-sectional study","volume":"105","author":"Kumar","year":"2020","journal-title":"Epilepsy Behav."},{"issue":"1","key":"10.1016\/j.seizure.2020.09.008_bib0120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euroneuro.2018.10.010","article-title":"Cutaneous adverse drug reactions to psychotropic drugs and their risk factors \u2013 a case-control study","volume":"29","author":"Greil","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.seizure.2020.09.008_bib0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.yebeh.2018.01.039","article-title":"Antiepileptic drug treatment of generalized tonic\u2013clonic seizures: an evaluation of regulatory data and five criteria for drug selection","volume":"82","author":"Shorvon","year":"2018","journal-title":"Epilepsy Behav."},{"issue":"3","key":"10.1016\/j.seizure.2020.09.008_bib0130","first-page":"57","article-title":"Valproic acid utilization among girls and women in Stockholm: impact of regulatory restrictions","volume":"3","author":"Karlsson Lind","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.09.008_bib0135","article-title":"Expert opinion: use of valproate in girls and women of childbearing potential with epilepsy: recommendations and alternatives based on a review of the literature and clinical experience\u2014a European perspective","author":"Toledo","year":"2020","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.seizure.2020.09.008_bib0140","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/ane.13231","article-title":"Valproate risk form\u2014Surveying 215 clinicians involving 4775 encounters","volume":"141","author":"Angus-Leppan","year":"2020","journal-title":"Acta Neurol. Scand."}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120302776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120302776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:55:46Z","timestamp":1761011746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131120302776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":28,"alternative-id":["S1059131120302776"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2020.09.008","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-benefit assessment of treatment of epileptic women of childbearing age with valproic acid","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2020.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}